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Background. A prospective screening study was carried out at the regional genetic and peri-
natal center in South Hungary in order to determine the efficiency of first-trimester nuchal
translucency screening for fetal aneuploidies, following augmentation of the availability of
nuchal translucency screening in the region by the inclusion of newly-trained hospital sono-
graphers.
Methods. Nuchal translucency thickness was measured by transvaginal sonography in 7,044
women with singleton or multiple pregnancies at weeks 10–12. Fetal karyotyping was per-
formed when the nuchal translucency was Ø2.5 mm, and in women with fetuses at high
cytogenetic risk.
Results. Follow-up was performed in 6,841 of the 7,044 screened women. An abnormal karyo-
type was found in 33 cases (0.48%). The level of increased nuchal translucency was 4.5% at
a cutoff of Ø2.5 mm, and 2.8% at a cutoff of Ø3 mm. Seventeen cases of trisomy 21, eight
of trisomy 18, four of trisomy 13, one of 45,X, one of triploidy and two cases with other
chromosomal abnormalities were detected. In the 33 fetuses with a chromosomal abnormality,
the nuchal translucency thickness was ,2.5 mm in a case of trisomy 18, Ø2.5 mm in 32 cases
and Ø3 mm in 28 cases. With cutoffs of 2.5 mm and 3 mm, the sensitivity was 96.97% and
84.85%, respectively.
Conclusions. Application of a nuchal translucency thickness cutoff of 2.5 mm is highly ef-
ficient for the screening of fetal aneuploidies at 10–12 weeks. This efficiency can be maintained
by increasing the regional availability of nuchal translucency screening through the inclusion
of newly-trained hospital sonographers.
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The increased accumulation of nuchal fluid in the
first-trimester fetus (1), called increased nuchal
translucency (NT) in consequence of its ultrasono-
graphic feature (2), has proved to be a very ef-
ficient marker for the screening of trisomy 21,
other fetal aneuploidies (2–4), fetal cardiac defects
Abbreviations:
NT: nuchal translucency; CVS: chorionic villus sampling; AC:
amniocentesis; CC: cordocentesis; AFP: alfa-fetoprotein.
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(5, 6), certain genetic syndromes (5–7) and struc-
tural abnormalities (5, 6, 8) in clinical studies (5–
16). For this reason, the method is currently at the
focus of international interest, in particular be-
cause the fetal NT screening yields different rates
of efficiency in different hands.
Our prenatal center was among the first to intro-
duce first-trimester ultrasound screening, and has
maintained a high rate of efficiency from the start
(1, 3, 15). The present paper reports on four years
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of experience with the method, following the
change-over from single-center screening with two
operators to four-center screening involving the in-
clusion of six newly-trained operators; a NT thick-
ness cutoff of 2.5 mm was used. The computer-
estimated risk (developed and provided by the Fe-
tal Medicine Foundation and Harris Birthright
Research Center for Fetal Medicine, London, UK)
was introduced from October, 1997 to facilitate
genetic counseling and decisions relating to invas-
ive tests.
Material and methods
In a prospective screening study between 1995 and
1998 at the Szeged Univeristy Prenatal Clinic and
at four regional hospitals, the NT thickness was
measured at 10–12 weeks of gestation by transva-
ginal ultrasound examination in 7,044 women with
singleton or multiple pregnancies. Informed con-
sent was obtained before ultrasound examinations
and invasive testing, and all the women partici-
pated in the study voluntarily.
The study did not cover the whole population of
the region, in spite of the increasing quantity of
available information on the importance of first-
trimester ultrasound screening.
The ultrasound examinations were performed
by using a 6.5–7.5 MHz vaginal probe (Combison
530, 3D, Kretz Technik). The NT thickness was
measured at 10–12 weeks of gestation between the
outer skin surface and the soft tissue overlying the
fetal spine in the sagittal plane of the fetus in a
‘quiet or neutral’ position. The maximal zoom of
the ultrasound screen was used. The fetal NT
thickness was evaluated only after embryo move-
ments, in order to distinguish between the fetal
skin contour and the amnion. The number of
fetuses, the crown-rump length, the fetal move-
ment and heart activity, the extremities and fetal
structural anomalies were also evaluated. Nuchal
translucency thicknesses of Ø2.5 mm were defined
as positive cases and were referred from the re-
gional hospitals to our tertiary genetic counseling
clinic for consideration of an invasive test.
All the sonographers involved had received a li-
cense for first-trimester scanning after theoretical
and practical training at our center. Theoretical
courses were held twice a year, while practical
training was continuous.
Invasive tests were offered according to the
classical genetic indications, i.e. a maternal age
Ø35 years, a previous child with chromosomal ab-
normalities, parental chromosomal abnormalities,
and a NT Ø2.5 mm. The policy of offering invasive
tests was as follows: an earlier rapid test (chorionic
villus sampling (CVS)) was advised when the NT
C Acta Obstet Gynecol Scand 80 (2001)
was Ø3 mm, irrespective of the maternal age.
Women with a NT between 2.5 and 2.9 mm could
choose from among CVS, amniocentesis (AC) or
cordocentesis (CC). Invasive tests were offered to
patients over 35 years of age, irrespective of the
NT, in accordance with the current legal regula-
tions in Hungary. The invasive procedures were
performed transabdominally with ultrasonically
guided needles, using a free hand technique. The
outer diameters of the CVS, AC and CC needles
were 1.1 mm, 0.8 mm and 0.8 mm, respectively.
For those who declined invasive tests, a thor-
ough ultrasound follow-up was advised in order to
seek early second-trimester markers of fetal aneu-
ploidies such as an increased NT, cardiac defects,
echogenic bowels, pyelectasis, and other structural
defects, combined with the alfa-fetoprotein (AFP)
level at 16 weeks of gestation. All other women
underwent an anomaly scan at weeks 18–20.
Information on the pregnancy follow-up and
outcome was obtained through written ques-
tionnaires or by telephone from the patients, from
the regional hospitals and/or from the nursing
midwife network.
From October 1997, we used in parallel the USS
program kindly provided by Professor Nicolaides
from the Fetal Medicine Foundation, London, but
the NT thickness of 2.5 mm remained as an inter-
ventional cutoff.
Results
Between January 1995 and December 1998, 7,044
women were enrolled in the first-trimester ultra-
sound screening study. Of these, 203 pregnancies
were excluded from further analysis since it was
impossible to obtain any written or oral infor-
mation concerning the pregnancy outcome.
As regards the remaining 6,841 pregnancies,
4,821 were examined in the regional centers and
2,020 (29.5%) were referred to or primarily exam-
ined at the Department of Obstetrics and Gyne-
cology. There were 6,750 (98.67%) singleton and 91
(1.33%) multiple pregnancies (85 sets of twins,
three sets of triplets, two sets of quadruplets and
one set of quintuplets). The two sets of quad-
ruplets and the quintuplet pregnancy were each re-
duced to two fetuses at the request of the parents.
All these multiplets were euploid. Spontaneous
abortion occurred between the NT screening and
the planned invasive tests in eight patients, and up
to week 20 in another 15 pregnancies.
The median maternal age was 31 years (range
16–46). The NT was Ø3 mm in 191 (2.8%) and
Ø2.5 mm in 308 (4.5%) cases (Table I), to whom
invasive tests were offered; however, 54 declined.
Six hundred and seven (8.87%) of the screened
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Table I. Distribution of nuchal translucency among pregnant women screened
during the first trimester
Nuchal Total number
translucency (mm) ,35 years Ø35 years of cases
0–0.9 773 288 1,061
1–1.9 2,673 1,638 4,311
2–2.4 686 475 1,161
Total ,2.5 mm 4,132 (97.43%) 2,401 (92.35%) 6,533 (95.5%)
2.5–2.9 54 63 117
3–3.9 24 91 115
4–4.9 11 24 35
5–5.9 9 11 20
6–6.9 5 7 12
7–7.9 2 2 4
8–8.9 2 1 3
9pi 2 0 2
Total Ø2.5 mm 109 (2.57%) 199 (7.65%) 308 (4.5%)
Total: 4,241 2,600 6,841
women underwent invasive genetic tests: 463 in-
volved CVS, 97 AC and 47 CC. Two hundred and
fifty-four of the 607 invasive tests were based on a
Table II. Chromosomal aneuploidies screened by nuchal translucency measurement at a gestational age of 70–91 days
Maternal age Gestational age Nuchal translucency
Serial number (years) (days) (mm) Karyotype
1 42 86 2.5 47,XXpi21
2 33 71 2.8 47,XYpi21
3 36 91 2.8 47,XYpi21
4 42 70 2.9 47,XYpi21
5 25 85 3 47,XXpi21
6 38 89 3.1 47,XYpi21
7 36 88 3.1 47,XYpi21
8 39 74 3.2 47,XXpi21
9 40 73 3.3 47,XYpi21
10 30 90 3.4 47,XYpi21
11 27 73 3.5 47,XYpi21
12 28 86 3.7 47,XXpi21
13 23 91 4 47,XYpi21
14 38 91 4 47,XYpi21
15 36 91 4.1 47,XXpi21
16 39 80 6.3 47,XXpi21
17 36 70 8.2 47,XYpi21
18 41 80 1.2 47,XYpi18
19 33 78 4.2 47,XYpi18
20 36 78 4.3 47,XXpi18
21 33 80 4.6 47,XYpi18
22 26 91 5.2 47,XXpi18
23 29 87 7.4 47,XYpi18
24 40 82 8 47,XXpi18
25 24 89 11.1 47,XYpi18
26 20 83 3.1 47,XYpi13
27 40 73 3.6 47,XXpi13
28 42 75 3.9 47,XYpi13
29 28 80 6.3 47,XYpi13
30 28 88 11 45,XO
31 39 91 3 46XX/46XY/ 47XXX/47XXY
32 24 89 8.5 69,XXX
33 35 90 3.5 47,XYpi14q partial trisomy
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NT thickness of Ø2.5 mm, 323 were based on mat-
ernal age (Ø35 years) alone (NT ,2.5 mm) and
30 were based on other indications (e.g. previous
parental or neonatal chromosomal abnormalities).
All those women who did not undergo invasive
tests gave birth to apparently normal neonates, as
checked by pediatricians.
An abnormal karyotype was found in 33
(0.48%) cases, i.e. 5.4% of the total number of
those who participated in invasive examinations
(Table II). A NT $2.5 mm was measured in 32
(96.97%) of the fetuses with an abnormal karyo-
type. For a cutoff of 3 mm, this changed to 84.8%.
In the group of invasive tests based on maternal
age and previous chromosomal abnormalities (353
cases), only one chromosomal aneuploidy was
found (Table II, serial number 18).
The mean NT values were 3.76 mm for trisomy
21, 5.75 mm for trisomy 18 and 4.23 mm for tri-
somy 13. The maternal age was Ø35 years in 18
(54.54%) of the 33 aneuploid pregnancies. A fetal
NT thickness ,3 mm (2.8 mm) was measured in
only one of the 15 mothers ,35 years of age (33
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Table III. Efficiency of nuchal translucency screening with a cutoff level of
Ø2.5 mm for all aneuploidies and trisomy 21
All aneuploidies (%) Trisomy 21 (%)
Sensitivity 96.97 100
Specificity 95.94 95.74
Positive predictive value 10.39 5.52
Negative predictive value 99.98 100
False-positive rate 4.05 4.26
Table IV. Efficiency of nuchal translucency screening with a cutoff level of Ø3
mm for all aneuploidies and trisomy 21
All aneuploidies (%) Trisomy 21 (%)
Sensitivity 84.85 76.47
Specificity 97.61 97.39
Positive predictive value 14.66 6.81
Negative predictive value 99.92 99.94
False-positive rate 2.39 2.61
years old), while four of the fetuses of the 18
women aged Ø35 years had a NT thickness ,3
mm (1.2, 2.5, 2.8 and 2.9 mm).
In the 191 (2.8%) fetuses where the NT was Ø3
mm, the prevalence of chromosomal defects was
14.7% (28 cases). When a cutoff of 2.5 mm was
applied (308 pregnant women), this figure changed
to 10.4% (32 cases).
Tables III and IV present the sensitivity, the
specificity, the positive and negative predictive
values and the false-positive rate for cutoff values
of 2.5 mm and 3 mm in all aneuploid cases and in
cases with trisomy 21.
Discussion
Efforts are currently being made worldwide to
achieve the recognition of fetal chromosomal
aneuploidies at the earliest possible gestational
age. Though a number of second-trimester ultra-
sonic markers of fetal aneuploidies have been de-
scribed, such as a thickened nuchal pad, heart de-
fects, a shorter humerus and femur, echogenic
bowels, pyelectasis, etc. (17–19), none of them is
specific and of value for efficient screening. More-
over, the search for these sonographic markers is
time-consuming, and demands exceptional train-
ing, qualifications, experience and competence in
ultrasound examinations.
The report by Szabo´ and Gelle´n (1990) (1) that
the accumulation of nuchal fluid Ø3 mm thick as
measured by high-resolution ultrasonography in
the first-trimester embryo is associated with tri-
somy 21 is gaining increasing acceptance world-
wide (2, 3, 5, 24, 29). First-trimester NT screening
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for chromosomal aneuploidies is ever more widely
utilized, but the efficiency is extremely variable: be-
tween 30 and 90% (2, 7, 10, 14, 20–28). In Szeged,
from the start we have placed special emphasis on
the analysis of factors influencing the efficiency,
and in the learning years we have maintained a
high rate of efficiency (88%) (15).
The Department of Medical Genetics is the only
center in South Hungary where all prenatal coun-
seling and cytogenetic studies are performed and
to which all neonates with any indications of ab-
normality are referred. The ultrasound clinic is a
third-level screening center.
Cutoff levels
The cutoff levels of first-trimester NT thickness
used by different authors range from 2 to 5 mm
(2, 7, 10, 20–26). In practice, we use a 2.5 mm cut-
off. Since the frequency of a NT thickness .3 mm
in the general population is 2–3%, invasive testing
of these selected pregnancies means an appreciable
load for genetic centers. If we use a lower cutoff,
we can detect more fetal aneuploidies, but the
workload increases significantly. A practically ac-
ceptable cutoff value is therefore necessary to dis-
tinguish affected cases from normal ones. It is
known that the NT thickness normally increases
with the crown-rump length (9), and the use of a
single cutoff may bias the sensitivity. If the NT
screening concentrates on weeks 11–12, a cutoff of
2.5 mm, which yields more than 90% sensitivity, is
acceptable in practice.
With a cutoff of 3 mm or higher (9, 13, 22),
the reported sensitivity for all aneuploidies ranges
between 46% and 69%, and that for trisomy 21
between 54% and 77%. The sensitivity we obtained
by using a 2.5 mm cutoff (96.97% for all aneu-
ploidies and 100% for trisomy 21) is highly com-
parable with the literature data.
Recent studies have used cutoff levels calculated
via percentile curves or the risk calculation pro-
gram of the Fetal Medicine Foundation, UK. This
program calculates the risk of aneuploidies from a
combination of the maternal age and the ges-
tational age-related prevalence, multiplied by a
likelihood ratio depending on the deviation from
the normal in NT thickness for the crown-rump
length. Use of a risk calculation involving a combi-
nation of the maternal age, gestational age, NT
thickness and former aneuploidy allowed the set-
ting-up of a risk cutoff level Ø1:300 (24). The
method of risk calculation reported by Snijders et
al. (1998) (24) is a more comprehensive approach,
which collects the known factors responsible for
the actual risk of aneuploidy. Their risk calculation
program led to a detection rate of 82% for Down
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syndrome and of 78% for other chromosomal
aneuploidies.
In our opinion, it is useful to set up a standard
of first-trimester ultrasound screening with a well-
defined cutoff level, as there are centers in the de-
veloping areas which do not have the facilities to
establish a computer calculation network. In ad-
dition, our study was conducted before the Fetal
Medicine Foundation risk calculation was avail-
able. A well-defined cutoff level is of practical
value for sonographers trained in NT measure-
ment who screen in underdeveloped regions far
from the centers and who need a practical solu-
tion. Our results suggest that 2.5 mm at 10–12
weeks of gestation is a reasonable cutoff level for
those who do not have the program as this yields
an acceptable rate of first-trimester detection of fe-
tal aneuploidies.
Efficiency of NT screening with a cutoff of 2.5 mm
Both in our regional perinatal center and in Hun-
gary overall, the proportion of pregnants aged over
35 years has been around 7% during the last dec-
ade. The regulations require that they should be
offered invasive tests, which result in only a 12–
15% detection rate of trisomy 21 at 50% uptake.
With a NT thickness of Ø2.5 mm, in the present
study 4.5% of all pregnancies screened positive and
they included 100% of the trisomy 21 cases and
96% of all aneuploidies. The sensitivity obtained
in literature studies lay in the range 50–92% for all
aneuploidies and 43–88% for trisomy 21 (2, 13, 15,
21, 22, 24).
In experienced hands, ultrasonographic evalu-
ation of the fetus at 10–12 gestational weeks is one
of the most efficient methods of screening chromo-
somal abnormalities. In the group of 353 women
with a NT thickness of ,2.5 mm who underwent
invasive tests, only one aneuploidy (trisomy 18)
was found; this suggests that the measurement of
NT thickness alone is a good selection criterion for
invasive tests. The method has no adverse effects
as concerns either the fetus or the pregnancy. A
NT cutoff of Ø2.5 mm is a sensitive and effective
criterion of selection of women for invasive tests.
The recognition of fetal aneuploidies at this ges-
tational age and the early termination of the
affected pregnancy may be less traumatic for
couples who choose this option and they may have
a healthy offspring sooner. A potential disadvan-
tage of this early diagnosis is the identification of
chromosomally abnormal pregnancies that are
destined to miscarry. About 40% of trisomy 21
fetuses die between 12 weeks of gestation and term
(30). Other benefits of the first-trimester scan in-
clude the confirmation that the fetus is alive, accu-
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rate dating of the pregnancy, the early diagnosis of
multiple pregnancies and the detection of major
structural abnormalities and missed abortion (6–
8, 16, 31). General evaluation of the fetal structure
simultaneously with NT measurement can reveal
other structural abnormalities and allow efficient
genetic counseling to be extended to more and
more women, irrespective of their age.
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